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Abstract Recognition signals are displayed on the cell surface
during apoptosis that enable macrophages to engulf and dispose
of the dying cell. A common signal is the externalization of
phosphatidylserine (PS). Studies in erythrocytes and platelets
have suggested that PS exposure requires the concomitant
activation of a phospholipid scramblase (PLS) and inhibition of
an adenosine triphosphate (ATP)-dependent aminophospholipid
translocase. However, the molecular mechanism underlying PS
exposure during apoptosis remains poorly understood. In this
study, we provide evidence that expression of PLS is neither
necessary nor sufficient for PS exposure during Fas-triggered
apoptosis. On the other hand, egress of PS is shown to correlate
with a decline in intracellular ATP and inhibition of amino-
phospholipid translocase activity upon Fas stimulation. More-
over, suppression of intracellular ATP levels by the glucose anti-
metabolite, 2-deoxyglucose, alone or in combination with
glucose-free medium, potentiates Fas-induced PS exposure in
the PLS-expressing Jurkat cell line and enables PLS-defec-
tive Raji cells to externalize PS in response to Fas ligation.
These studies suggest that intracellular ATP levels can modulate
the externalization of PS during apoptosis, and implicate
the ATP-dependent aminophospholipid translocase in this
process. - 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Eukaryotic cells are characterized by an asymmetric distri-
bution of their membrane phospholipids [1]. Hence, the ami-
nophospholipids phosphatidylserine (PS) and phosphatidyl-
ethanolamine (PE) are normally con¢ned to the inner lea£et
of the plasma membrane, whereas phosphatidylcholine and
sphingomyelin are located predominantly in the outer lea£et.
Phospholipid asymmetry is relatively stable and is believed to
be maintained by an aminophospholipid translocase, which
speci¢cally transports PS and PE from the outer to the inner
lea£et of the plasma membrane [2]. This adenosine triphos-
phate (ATP)-dependent and Ca2þ-inhibitable enzyme activity
is sensitive to the sulfhydryl-reactive agent N-ethylmaleimide
(NEM) and to vanadate, an inhibitor of P-type ATPases [2].
A candidate protein termed ATPase II with phospholipid
transporting properties was recently identi¢ed, yet whether
or not this protein is responsible for aminophospholipid trans-
location in the plasma membrane remains to be determined
[3,4].
Externalization of PS has been shown to occur in activated
platelets and in aging erythrocytes and serves to stimulate the
coagulation cascade and mediate cell recognition by macro-
phages, respectively [2]. PS externalization is also a common
event during apoptosis [5,6], and previous studies have dem-
onstrated that PS exposure in cells undergoing apoptosis is
caspase-dependent and requires extracellular Ca2þ [7^9]. The
rapid externalization of PS during platelet activation is
thought to be mediated by a Ca2þ-dependent plasma mem-
brane protein, phospholipid scramblase (PLS), which cata-
lyzes the bidirectional movement of phospholipids between
membrane lea£ets [2]. Zhao et al. [10] have recently docu-
mented a close correlation between Ca2þ ionophore-triggered
PS exposure and the expression of PLS in a number of tumor
cell lines. However, we have previously shown that expression
of PLS in tumor cells does not correlate with the external-
ization of PS in response to Fas stimulation [11]. These ob-
servations, which have been corroborated in recent studies by
other investigators [12], thus indicate that the mechanism of
delayed PS exposure during apoptosis di¡ers from the rapid,
Ca2þ-stimulated PS exposure evidenced in activated platelets.
In the present study, we sought to further characterize the
mechanism of Fas-induced exposure of PS using two Fas-sen-
sitive cell lines expressing di¡erent levels of PLS. Our data
show that expression of PLS is neither necessary nor su⁄cient
for PS exposure during apoptosis, and suggest that inhibition
of the ATP-dependent aminophospholipid translocase plays a
critical role in the process of PS externalization.
2. Materials and methods
2.1. Reagents and cell culture
Anti-Fas monoclonal antibodies (clone CH-11) were purchased
from Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan).
zVAD-fmk (benzyloxycarbonyl-Val-Ala-Asp-£uoromethylketone) and
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DEVD-AMC (Asp-Glu-Val-Asp-7-amino-4-methylcoumarin) were
obtained from Enzyme Systems Products (Dublin, CA, USA) and
Peptide Institute, Inc. (Osaka, Japan), respectively. NEM, 2-deoxyglu-
cose (2-DG) and oligomycin were purchased from Sigma (St. Louis,
MO, USA). Recombinant human interferon (IFN)-K was kindly pro-
vided by Dr. Stefan Einhorn, Karolinska Hospital, Stockholm, Swe-
den. The human leukemic T cell line Jurkat and the EBV-transformed
human B cell line Raji were from the European Collection of Cell
Cultures (Salisbury, UK). Cells were cultured in RPMI-1640 medium
(Sigma) supplemented with 10% heat-inactivated fetal bovine serum
and 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin
(Life Technologies).
2.2. PS exposure
Exposure of PS was determined by the binding of FLUOS-coupled
annexin V (Boehringer Mannheim, Mannheim, Germany) according
to the manufacturer’s protocol. Brie£y, treated cells (0.5U106) were
washed and resuspended in binding bu¡er containing annexin V-
FLUOS and propidium iodide for 10 min prior to analysis. Ten
thousand events were collected on a FACScan £ow cytometer (Becton
Dickinson, San Jose, CA, USA) equipped with a 488 nm argon laser,
and analyzed using the CellQuest software (Becton Dickinson). Low-
£uorescence debris and necrotic cells, de¢ned as cells that had lost
their membrane integrity and thus were permeable to propidium io-
dide, were gated out prior to analysis.
2.3. Caspase activity
The measurement of DEVD-AMC cleavage was performed in a
£uorometric assay as previously described [11]. Brie£y, cell lysates
(1.0U106) and substrates were combined in a reaction bu¡er (100
mM HEPES, 10% sucrose, 5 mM dithiothreitol, 1036% NP-40 and
0.1% CHAPS; pH 7.25) and added to a microtiter plate. AMC lib-
eration was monitored in a Fluoroscan II plate reader (Labsystems,
Stockholm, Sweden) using 355 nm excitation and 460 nm emission
wavelengths. Fluorescence was measured every 70 s during a 30 min
period and £uorescence units were converted to pmol of AMC using a
standard curve generated with free AMC. Data from duplicate sam-
ples were then analyzed by linear regression.
2.4. Aminophospholipid translocase activity
Aminophospholipid translocase activity was measured as the up-
take of the £uorescence-labeled phospholipid 1-oleoyl-2-[6-[(7-nitro-
2-1,3-benzoxadiazol-4-yl) amino]caproyl]-sn-glycero-3-phosphoserine
(NBD-PS) (Avanti Polar-Lipids, Inc., Alabaster, AL, USA) as de-
scribed by Bratton et al. [13]. Brie£y, treated cells (5.0U105) were
washed once and resuspended in 50 Wl HEPES-bu¡ered saline
(HBS) (137 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 5 mM glucose,
10 mM HEPES, pH 7.4, with 1 mM CaCl2). The cells were incubated
with 1 Wl of NBD-PS (50 Wg/ml) and 1 Wl of propidium iodide (250 Wg/
ml) for 10 min at room temperature, followed by back extraction with
50 Wl of 1% bovine serum albumin (BSA) in HBS for 5 min. Samples
were then transferred to ice, 900 Wl of ice-cold HBS was added and
analysis was performed on a FACScan £ow cytometer (Becton Dick-
inson, San Jose, CA, USA).
2.5. ATP determination
ATP concentrations were determined in a luminometric assay using
the ATP dependency of the light-emitting luciferase-catalyzed oxida-
tion of luciferin (Boehringer Mannheim, Mannheim, Germany) ac-
cording to the manufacturer’s protocol. Brie£y, cells (5.0U104) were
Fig. 1. Fas-triggered PS exposure in Jurkat, but not in Raji cells : induction of PLS fails to facilitate PS exposure in Raji cells. A: Caspase
3-like activity, expressed as pmol of AMC released per min, in cells treated with anti-Fas antibodies (250 ng/ml) for 4 h in the presence or ab-
sence of zVAD-fmk (10 WM). Data are expressed as meanQS.D. (n=3). B: PS exposure, as detected by £ow cytometric analysis of annexin V
binding, in Jurkat and Raji cells treated as above. The percentage of annexin V-positive cells in each sample is indicated. Data are representa-
tive of at least ¢ve separate experiments. C: Western blot analysis of PLS expression (35 kDa) in equal numbers of untreated Jurkat and Raji
cells. D: Upregulation of endogenous PLS in Raji cells upon stimulation with IFN-K (1000 IU/ml) for 6 h. Cell lysates derived from an equal
number of cells were loaded in each lane. E: Annexin V staining of Raji cells incubated in the presence or absence of IFN-K as above and
then stimulated with anti-Fas antibodies (250 ng/ml) for 6 h. Data shown are representative of at least four separate experiments.
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added to 1 ml of boiling lysing bu¡er (100 mM Tris, 4 mM EDTA,
pH 7.75), samples were incubated for another 2 min at 100‡C and 50
Wl were taken out to a 96-well plate. Prior to measurement, 50 Wl of
luciferase were added to each well and the plate was analyzed in a
luminometer (Anthos, Labtec Instruments, Austria).
2.6. Reverse transcription (RT)-PCR
Total RNA was isolated from 107 cells, using the RNeasy Mini kit
(Qiagen) according to the manufacturer’s protocol. 5 Wg of total RNA
were subjected to RT coupled with a PCR reaction, performed in a
DNA Thermal Cycler 480 (Perkin Elmer), using the SuperScript II
RNase H3 RT-PCR system (Life Technologies). Primers used for
ATPase II were: P1 (sense primer) 5P-CTG GTA CTC TGA CAT
GCA ATG-3P and P2 (antisense primer) 5P-GAG ATT TTC CAG
CAA TGA TGA ATC-3P (Life Technologies) [4]. The cycling condi-
tions were 94‡C for 3 min and n (24^27) cycles consisting of 94‡C for
15 s, 55‡C for 30 s and 72‡C for 30 s. After the last cycle, incubation
at 72‡C was prolonged for 7 min. PCR reactions for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were performed separately using
the following primers: 5P-ACC ACA GTC CAT GCC ATC AC-3P
and 5P-TCC ACC ACC CTG TTG CTG TA-3P (Life Technologies).
The cycling conditions were 94‡C for 3 min and 19 cycles of 94‡C for
30 s, 60‡C for 30 s and 72‡C for 45 s. Again, incubation at 72‡C was
prolonged for 7 min after the last cycle. PCR products (170 and 452
bp, respectively) were resolved on a 2.5% agarose gel and visualized
with ethidium bromide staining. The intensity of the bands was quan-
ti¢ed using a Gel-Doc densitometer (Bio-Rad) connected to the Mo-
lecular Analyst software.
2.7. Western blot
For protein detection, samples were solubilized for 5 min at 100‡C
in Laemmli bu¡er. Proteins were then separated at 130 V on 12%
SDS^polyacrylamide gels and electrophoretically transferred to nitro-
cellulose ¢lters for 2 h at 100 V. Membranes were blocked overnight
in 1% BSA and 5% non-fat dried milk and then incubated for 1 h with
monoclonal antibodies against PLS (1:1000; provided by Dr. Peter
Sims, The Scripps Research Institute, La Jolla, CA, USA) or poly-
clonal antibodies directed against GAPDH (1:3000; Trevigen, Gai-
thersburg, MD, USA). After washing, the membranes were incubated
with a peroxidase-conjugated secondary antibody (1:10 000; Pierce,
Rockford, IL, USA) and bound antibody was visualized by enhanced
chemiluminescence (Amersham Corp., Buckinghamshire, UK) accord-
ing to the manufacturer’s instructions.
3. Results
3.1. Fas-triggered PS exposure in Jurkat, but not in Raji cells:
induction of PLS fails to facilitate PS exposure
Jurkat and Raji cells both readily undergo apoptosis with
attendant activation of caspase 3-like enzymes in response to
Fas ligation, yet only Jurkat cells externalize PS (Fig. 1A,B).
As expected, the broad range caspase inhibitor, zVAD-fmk
(10 WM), which blocks hydrolysis of the caspase substrate
DEVD-AMC (Fig. 1A), prevented PS exposure in Jurkat cells
(Fig. 1B). PLS is known to regulate PS externalization in
response to Ca2þ stimulation [2]. Interestingly, Raji cells ex-
press very low levels of PLS while this protein is readily de-
tected in Jurkat cells (Fig. 1C). However, in line with previous
studies [11], induction of PLS by IFN-K (1000 IU/ml) stimu-
lation of Raji cells did not confer the ability to expose PS
upon Fas ligation (Fig. 1D,E). Due to a lack of suitable re-
agents, we were unable to determine the level of expression of
the candidate aminophospholipid translocase, ATPase II, in
Jurkat and Raji cells. RT-PCR analyses, on the other hand,
revealed the presence of ATPase II mRNA in both cell lines,
with an almost two-fold higher level of mRNA in Raji cells
(Fig. 2A,B). Moreover, incubation of Jurkat and Raji cells
with the thiol-reactive agent NEM (5 mM), a known inhibitor
of the aminophospholipid translocase, resulted in a time-de-
pendent induction of PS exposure in both cell lines (Fig. 2C).
Taken together, these observations suggest that expression of
Fig. 2. Expression of the candidate aminophospholipid translocase, ATPase II, in Jurkat and Raji cells, and induction of PS exposure in both
cell lines following NEM treatment. A: Total RNA from Jurkat and Raji cells was submitted to RT and PCR for 24^27 cycles using ATPase
II-speci¢c primers and PCR products were resolved on an agarose gel. B: Ratio between ATPase II after 27 PCR cycles and the internal con-
trol GAPDH. Data are representative of three independent experiments. C: Annexin V staining of Jurkat and Raji cells upon incubation with
NEM (5 mM), an inhibitor of aminophospholipid translocation. Data are representative of four separate experiments.
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PLS is not su⁄cient for apoptotic PS exposure, and empha-
size the importance of inhibition of the aminophospholipid
translocase, and/or of other thiol-dependent processes, for
cell surface exposure of PS.
3.2. Fas-mediated decline in ATP and concomitant suppression
of the aminophospholipid translocase correlates with the
ability to externalize PS
To determine aminophospholipid translocase activity in
Jurkat and Raji cells, we measured uptake of exogenous, £uo-
rescently labeled NBD-PS. As seen in Fig. 3A, NEM (5 mM)
blocked translocation of NBD-PS in both cell lines. In Jurkat
cells, a time-dependent decrease in aminophospholipid trans-
locase activity was observed upon Fas-triggering (Fig. 3B). In
contrast, in Raji cells stimulated with anti-Fas antibodies,
translocase activity was inhibited to a much lesser degree.
Importantly, Fas-mediated suppression of translocase activity
in Jurkat cells was completely abrogated by zVAD-fmk (Fig.
3B). Previous studies in erythrocytes have demonstrated that
the inward movement of PS across the plasma membrane is
inhibited by decreased levels of ATP [2]. These observations
prompted us to study the level of intracellular ATP in Jurkat
and Raji cells in response to Fas ligation. As shown in Fig.
3C, the ATP level in Jurkat cells decreased prominently dur-
Fig. 3. PS exposure correlates with the Fas-triggered inhibition of aminophospholipid translocation and concomitant decline in intracellular
ATP. Aminophospholipid translocase activity, as measured by the uptake of exogenous NBD-PS, was determined in Jurkat and Raji cells
treated with (A) NEM for 5 min at 0.5 and 0.1 mM, respectively, or (B) anti-Fas antibodies (250 ng/ml) for the indicated times. Samples incu-
bated for 3 h in the presence of zVAD-fmk (10 WM) plus anti-Fas antibodies are also shown. Values are given as the number of cells with
NBD-PS uptake (% of control). C: Jurkat and Raji cells were incubated with anti-Fas antibodies (250 ng/ml) for the indicated times and intra-
cellular ATP levels were analyzed using the luciferase-based luminometric assay. ATP concentrations are expressed as the percentage of un-
treated controls. D: Intracellular ATP concentrations were determined in cells incubated in the presence or absence of 2-DG (5 mM) for 24 h.
Jurkat cells preincubated in the presence or absence of 2-DG for 24 h and incubated with anti-Fas antibodies (250 ng/ml) for the indicated
times, were assessed for aminophospholipid translocation (E) and PS externalization (F) by determination of NBD-PS uptake and annexin V
staining, respectively. Data in B^F are shown as meanQS.D. (n=3^4).
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ing the time of incubation with anti-Fas antibodies. However,
ATP levels in Raji cells were maintained approximately at
control values up to 4 h after apoptosis induction. To further
investigate the relationship between ATP levels and PS expo-
sure, both cell lines were incubated in medium containing
2-DG, a glucose analogue which competitively inhibits cellu-
lar uptake and utilization of glucose. Incubation with 2-DG
for 24 h yielded a signi¢cant decrease in the level of ATP both
in Jurkat and Raji cells (Fig. 3D). Moreover, preincubation of
Jurkat cells with 2-DG, followed by Fas stimulation, potenti-
ated the inhibition of aminophospholipid translocase activity
as well as the degree of PS exposure (Fig. 3E,F). These events
were accompanied by an increase in caspase-3-like activity, as
determined by hydrolysis of the peptide substrate DEVD-
AMC (data not shown). The present data thus demonstrate
that Fas-triggered PS exposure can be modulated in Jurkat
cells through suppression of intracellular ATP with concom-
itant inhibition of aminophospholipid translocase activity.
3.3. Fas triggering of PLS-defective Raji cells under conditions
of low intracellular ATP yields apoptotic PS exposure
To investigate whether suppression of intracellular ATP
levels would promote Fas-mediated PS exposure also in Raji
cells, these cells were preincubated in glucose-free medium in
combination with 2-DG for 24 h prior to stimulation with
anti-Fas antibodies. These conditions dramatically enhanced
the Fas-induced decrease in intracellular ATP (6 10% of ATP
compared to untreated cells maintained in regular medium),
and potentiated the Fas-induced inhibition of aminophospho-
lipid translocase activity seen in these cells under normal in-
cubation conditions (Fig. 4A). Remarkably, a fraction of Raji
cells now exposed PS upon Fas ligation (Fig. 4C). This cell
population was clearly apoptotic since cells were positive for
annexin V yet remained negative for propidium iodide up-
take; moreover, these cells maintained Fas-induced activation
of caspase-3-like enzymes (Fig. 4B,C). By contrast, preincu-
bation of Raji cells in glucose-free medium containing oligo-
mycin, an inhibitor of the mitochondrial F0F1-ATPase, to
deplete cells of ATP, resulted in the induction of necrosis
and absence of caspase activation upon Fas stimulation
(Fig. 4B,C). The latter data are thus consistent with previous
studies in which ATP depletion was shown to redirect the
mode of cell death from apoptosis to necrosis [14]. In sum,
PLS-defective Raji cells, which normally fail to expose PS in
response to Fas triggering, can do so when stimulated under
conditions of low ATP.
4. Discussion
Previous studies have suggested that the concomitant inhi-
bition of aminophospholipid translocation and activation of
non-speci¢c transbilayer movement of phospholipids (scram-
bling) coordinates the externalization of PS in cells under-
going apoptosis [15]. Furthermore, Bratton et al. [13] have
proposed that loss of translocase activity is necessary, but
not su⁄cient, for the appearance of PS on the surface of ap-
optotic cells and suggested that the activation of a scramblase
(PLS) is required for PS exposure to occur. In contrast, we
show herein that IFN-K-induced expression of PLS in Raji
cells is insu⁄cient for apoptotic PS exposure and provide
evidence that Fas-triggered PS exposure is governed by the
level of intracellular ATP in Jurkat and Raji cells, irrespective
of PLS expression. Importantly, NEM, a thiol-reactive agent
commonly used to inhibit aminophospholipid translocation
[16], induced externalization of PS in both cell lines, in the
absence of other signs of apoptosis. Moreover, suppression of
Fig. 4. Fas ligation triggers PS exposure in PLS-defective Raji cells under conditions of low intracellular ATP. Raji cells were preincubated ei-
ther in regular medium (normal ATP) for 24 h, in glucose-free medium plus 2-DG (5 mM) for 24 h (low ATP), or in glucose-free medium plus
oligomycin (10 WM) for 45 min (ATP depletion), and then incubated in the absence or presence of anti-Fas antibodies (250 ng/ml) for a further
12 h (normal ATP, low ATP) or 6 h (ATP depletion). Cells were subsequently analyzed for (A) aminophospholipid translocase activity, (B) acti-
vation of caspase-3-like enzymes, and (C) PS exposure, as described in Section 2. For clarity, necrotic cells were gated out in all samples prior
to analysis of annexin V staining except in the case of Fas-triggered cells incubated under ATP-depleting conditions, for which only cell debris
were excluded. Data shown in A and B are expressed as meanQS.D. (n=3). Data in C are representative of at least three independent experi-
ments. n.d., not detectable.
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intracellular ATP levels potentiated translocase inhibition and
PS exposure in Jurkat cells, and yielded Fas-induced PS ex-
posure in the otherwise PS exposure-incompetent Raji cells.
While we cannot exclude an e¡ect on other ATP-dependent
cellular processes, the current data nevertheless suggest that
inhibition of the ATP-dependent aminophospholipid translo-
case, perhaps related to the inhibition of ATPase II, is su⁄-
cient to promote PS exposure during apoptosis.
As mentioned above, PLS activation is known to be in-
volved in Ca2þ-stimulated PS exposure in activated platelets
[2]. The current data obtained in Jurkat and Raji cells thus
indicate that the mechanism of apoptotic PS exposure di¡ers
from the one evidenced in activated platelets insofar as ex-
pression of PLS appears to be dispensible in the former case.
In further support of this view, Li and Tait [17] previously
reported that anti-CD9 antibodies inhibit Ca2þ-stimulated PS
exposure in Jurkat cells while PS exposure triggered by vari-
ous apoptotic stimuli was una¡ected. Interestingly, during the
preparation of this manuscript, Silverman et al. [18] reported
that IFN-K-inducible PLS a¡ects the growth of human ovar-
ian carcinoma cells in nude mice. While the mechanism by
which PLS exerts its putative tumor suppressive function re-
mains unresolved, these ¢ndings nevertheless support the no-
tion that PLS may have alternative role(s), unrelated to PS
externalization, in nucleated cells. Further elucidation of the
di¡erent pathways that mediate PS externalization is expected
to have important implications for our understanding of the
recognition and clearance of dying cells, and may provide new
insights into the pathogenesis and treatment of diseases in
which cell clearance is perturbed.
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